


**Product Name** : MLN1117  
**Cat. No.** : PC-42947  
**CAS No.** : 1268454-23-4  
**Molecular Formula** : C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 363.37  
**Target** : PI3K  
**Solubility** :



## Biological Activity

MLN1117 (INK1117, TAK-117, Serabelisib) is a potent, selective **PI3K p110 $\alpha$**  inhibitor with IC<sub>50</sub> of 15 nM, displays >300-fold selectivity over p110 $\beta/\gamma/\delta$  and mTOR.

MLN1117 (INK1117, TAK-117, Serabelisib) inhibits AKT phosphorylation and growth in PIK3CA mutant breast cancer cells with IC<sub>50</sub> of 2  $\mu$ M, significantly suppresses B cell proliferation driven by anti-IgM alone but not by anti-IgM plus IL-4.

MLN1117 (INK1117, TAK-117, Serabelisib) abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma combined with alisertib.

## References

So L, et al. *J Biol Chem*. 2013 Feb 22;288(8):5718-31.

Juric D, et al. *Clin Cancer Res*. 2017 Sep 1;23(17):5015-5023.

Islam S, et al. *Oncotarget*. 2017 Nov 1;8(59):100326-100338.

Yea SS, et al. *PLoS One*. 2014 Jun 10;9(6):e99486.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com